Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 913 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-related Macular Degeneration
Interventions
E10030
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
ADX-038, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
21
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 18 more
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Neovascular Age Related Macular Degeneration
Interventions
RTH258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia
Conditions
Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions
Interferon gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Macular Edema
Interventions
GSK2798745
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Sacramento, California • Lake Worth, Florida • Winter Haven, Florida + 3 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
331,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Conditions
Cystoid Macular Edema, Diabetic Macular Edema
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Bakersfield, California • Santa Barbara, California
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
LMG324, Ranibizumab 0.5 mg, Sham
Biological
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
Drug
Lead sponsor
Light Sciences LLC
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Human Central Nervous System Stem Cells
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
51 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Wet Age-related Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
65
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Conditions
Macular Degeneration
Interventions
pazopanib eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Miami, Florida • Winter Haven, Florida + 6 more
Conditions
Age-Related Macular Degeneration
Interventions
FORESEE HOME
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Toms River, New Jersey
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Proteomics Testing In Chronic Atrophy

NCT07298291
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
AC Tap (anterior chamber paracenthesis)
Procedure
Lead sponsor
ClinOmicsAI
Network
Eligibility
50 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Erie, Pennsylvania
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Macular Edema
Interventions
dexamethasone 700 ㎍ intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York